Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Zendy

Robert J. Motzer | Zendy; Bernard Escudier | Zendy; Ray McDermott | Zendy; Saby George | Zendy; Hans J. Hammers | Zendy; Sandhya Srinivas | Zendy; Scott S. Tykodi | Zendy; Jeffrey A. Sosman | Zendy; Giuseppe Procopio | Zendy; Elizabeth R. Plimack | Zendy; Daniel Castellano | Zendy; Toni K. Choueiri | Zendy; Howard Gurney | Zendy; Frede Donskov | Zendy; Petri Bono | Zendy; John Wagstaff | Zendy; Thomas Gauler | Zendy; Takeshi Ueda | Zendy; Yoshihiko Tomita | Zendy; Fabio A.B. Schutz | Zendy; Christian Kollmannsberger | Zendy; James Larkin | Zendy; Alain Ravaud | Zendy; Jason S. Simon | Zendy; Li-An Xu | Zendy; Ian M. Waxman | Zendy; Padmanee Sharma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Author(s) -

Robert J. Motzer,

Bernard Escudier,

Ray McDermott,

Saby George,

Hans J. Hammers,

Sandhya Srinivas,

Scott S. Tykodi,

Jeffrey A. Sosman,

Giuseppe Procopio,

Elizabeth R. Plimack,

Daniel Castellano,

Toni K. Choueiri,

Howard Gurney,

Frede Donskov,

Petri Bono,

John Wagstaff,

Thomas Gauler,

Takeshi Ueda,

Yoshihiko Tomita,

Fabio A.B. Schutz,

Christian Kollmannsberger,

James Larkin,

Alain Ravaud,

Jason S. Simon,

Li-An Xu,

Ian M. Waxman,

Padmanee Sharma

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1510665

Subject(s) - nivolumab , everolimus , renal cell carcinoma , medicine , oncology , carcinoma , urology , immunotherapy , cancer

Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research